证券代码：301022 证券简称：海泰科 公告编号：2025-187 青岛海泰科模塑科技股份有限公司 关于与关联方共同向参股子公司增资暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 3、公司股东及持股比例分别为： 一、关联交易概述 青岛海泰科模塑科技股份有限公司（以下简称"公司"）于 2025 年 12 月 17 日召 开第三届董事会第一次独立董事专门会议、第三届董事会第五次会议，审议通过了《关 于与关联方共同向参股子公司增资暨关联交易的议案》，为增强公司参股子公司海泰 科新材料泰国有限公司（以下简称"合资公司"）实力，同意公司全资子公司海泰科 模塑（泰国）有限公司（以下简称"海泰科（泰国）"）以自有资金与关联方青岛新材 料科技工业园发展有限公司（以下简称"新材料工业园"）以货币出资方式共同对合 资公司增资。增资前，合资公司总投资额为人民币 500.00 万元，其中新材料工业园出 资人民币 255.00 万元，持股 51.00%，海泰科（泰国）出资人民币 245.00 万元，持股 49.00%；增资后，合资公司总投资额为人民币 660.0 ...

Core Viewpoint - The company has developed PEEK modified materials that can meet some aerospace application technical requirements, but specific applications require targeted research and development [1] Group 1 - The company's modified plastic products currently do not have applications in the aerospace field [1]

Group 1 - The company has developed modified PEEK materials that can meet some aerospace application technical requirements, but specific applications require targeted research and development [2] - Currently, the company's modified plastic products do not have applications in the aerospace field [2]

格隆汇12月19日丨海泰科(301022.SZ)在互动平台表示，公司改性塑料产品暂无航天领域的应用。 （原标题：海泰科(301022.SZ)：改性塑料产品暂无航天领域的应用） ...

证券日报网讯12月18日，海泰科（301022）在互动平台回答投资者提问时表示，公司改性塑料已应用于 部分电子电器类产品的结构件、功能件，鉴于商业保密原则，公司不便透露与客户合作的具体信息。 ...

Group 1 - The core viewpoint of the article is that Hitec (301022.SZ) has stated that its modified plastic products currently do not have applications in the aviation sector [1] Group 2 - The company communicated this information through an investor interaction platform [1]

Core Viewpoint - The company Haitai Technology (301022.SZ) has announced a delay in the expected operational date of its high polymer new materials project from January 31, 2026, to January 31, 2028, due to adjustments in construction progress and market conditions [1] Group 1: Project Details - The project aims to achieve an annual production capacity of 150,000 tons of high polymer new materials [1] - As of November 30, 2025, the company has invested 122.0528 million yuan, which accounts for 31.19% of the planned total investment [1] - There remains 269.3228 million yuan of unutilized raised funds, which will continue to be used for project construction [1] Group 2: Reasons for Delay - The primary reason for the delay is to maintain the advanced nature of production equipment and processes, avoiding short-term overcapacity [1] - The company has decided to prudently adjust the investment pace, which involves a reduction in the implementation subject and location in Qingdao, Shandong Province, focusing resources on the construction of the production base in Shou County, Huainan City, Anhui Province [1]

证券日报网讯 12月17日，海泰科发布公告称，公司第三届董事会第五次会议审议通过《关于减少募投 项目实施主体、实施地点及延期的议案》《关于与关联方共同向参股子公司增资暨关联交易的议案》 《关于2026年度日常关联交易预计的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - CICC is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, with trading resuming on December 18, 2025 [1] - Victory Energy's major shareholder plans to transfer 29.99% of its shares to Qiteng Robotics, with no plans for asset restructuring in the next 12 months [2] - China Metallurgical Group intends to repurchase A-shares worth 1 to 2 billion yuan at a price not exceeding 4.9 yuan per share [3] Group 2 - Boten Co. plans to acquire part of the Yifeng Yunding Fund for 1 yuan, with a commitment to fulfill a 20 million yuan capital contribution [4] - Tongyou Technology has initiated a 50 million yuan accounts receivable factoring business [5] - Gaode Infrared has received approval to issue debt financing tools totaling up to 3 billion yuan [6] Group 3 - Zhengyu Industrial's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] - China CRRC signed contracts totaling approximately 53.31 billion yuan, accounting for 21.6% of its projected 2024 revenue [9] - High Energy Environment's director increased his stake by purchasing 56,100 shares [10] Group 4 - Shantou Technology received approval from the CSRC for a convertible bond issuance [11] - Puyang Co. plans to use up to 900 million yuan of idle funds for entrusted wealth management [12] - Huibai New Materials has been awarded a government subsidy of 3.8 million yuan, with the first installment of 2.12 million yuan already received [13] Group 5 - Jiayuan Technology's shareholders plan to transfer 2.51% of the company's shares through a pricing inquiry [14] - Lingpai Technology's subsidiary terminated a 125 million yuan procurement contract due to market changes [15] - Juguang Technology intends to use up to 200 million yuan of idle funds for cash management [16] Group 6 - Zhongwen Media's subsidiary terminated a 200 million yuan private equity fund subscription due to market changes [17] - Zhifei Biological's modified vaccine for monkeypox has received clinical trial acceptance [19] - GeKowei's subsidiary received a government subsidy of 60 million yuan, accounting for 32.12% of the company's audited net profit [20] Group 7 - Wantai Biological's application for a clinical trial of a respiratory syncytial virus vaccine has been accepted [21] - Haitai Technology plans to increase capital in its Thai joint venture from 500,000 to 3 million Thai baht [22] - Shanghai Airport signed contracts for the transfer of duty-free store operating rights [23] Group 8 - Del Shares received approval to issue shares for the acquisition of 100% of Aizhuo Intelligent [24] - Novozymes' products have obtained EU CE IVDR certification [25] - Shibai Testing's chairman's assistant plans to increase shareholding by 8 to 12 million yuan [26] Group 9 - Huitian New Materials plans to invest approximately 97.68 million yuan in a lithium battery anode glue project [27] - Pudong Construction's subsidiaries won contracts totaling 1.649 billion yuan [29] - Acolyte's subsidiary has entered trial production for a special high-temperature resistant resin project [30] Group 10 - Pingzhi Information's subsidiary signed a 38.25 million yuan computing power service contract [31] - Tianma Technology is required to pay 5.3625 million yuan in taxes and penalties [32] - Yahon Pharmaceutical's clinical trial application for GLX002 has been approved [34]

为增强合资公司实力，公司与新材料工业园拟签署《增资协议》，将合资公司的投资额由人民币500.00 万元增加至人民币660.00万元，并将合资公司的注册资本由500.00万泰铢增加至3,000.00万泰铢（具体金 额以泰国当地行政主管部门审批为准）。 格隆汇12月17日丨海泰科(301022.SZ)公布，公司于2025年5月经总经理办公会会议审批，同意由全资子 公司海泰科模塑（泰国）有限公司（简称"海泰科（泰国）"）以自有资金与青岛新材料科技工业园发展 有限公司（简称"新材料工业园"）在泰国共同投资设立海泰科新材料泰国有限公司（简称"合资公 司"），合资公司总投资额为人民币500.00万元，其中新材料工业园出资人民币255.00万元，持股 51.00%，海泰科（泰国）出资人民币245.00万元，持股49.00%。合资公司已于2025年5月29日取得泰国 当地行政主管部门颁发的注册文件。 ...